Literature DB >> 22776923

Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica.

Harold Merle1, Stéphane Olindo, Séverine Jeannin, Ruddy Valentino, Hossein Mehdaoui, Florence Cabot, Angélique Donnio, Rabih Hage, Raymond Richer, Didier Smadja, Philippe Cabre.   

Abstract

OBJECTIVE: To assess the contribution of plasma exchange (PE) in association (add-on) with pulsed intravenous corticosteroids in acute optic neuritis of neuromyelitis optica (NMO) and limited forms of NMO.
METHODS: Thirty-six patients with optic neuritis were treated from January 1, 1995, through December 31, 2010, with pulsed intravenous corticosteroids and 16 with pulsed intravenous corticosteroids plus PE. The ophthalmologic examination was performed at least 6 months after optic neuritis treatment. Visual acuity and visual field assessed with the Snellen scale and the logarithmic scale of the Early Treatment Diabetic Retinopathy Study were measured using standard automated perimetry and frequency doubling technology perimetry. Retinal peripapillary fiber thickness was measured using optical coherence tomography.
RESULTS: Final visual acuity was 20/400 in the corticosteroid group and 20/50 in the PE group (P=.04). The gain in visual acuity was 20/200 in the corticosteroid group and 20/30 in the PE group (P=.01). A poor final visual acuity outcome (≤20/200) was found in 19 of 36 patients (53%) in the corticosteroid group and 2 of 16 patients (13%) in the PE group (P=.008). Mean (SD) thickness of peripapillary retinal nervous fibers was 63.1 (20.4) μm in the corticosteroid group and 70.3 (20.3) μm in the PE group (P=.16). The mean (SD) thickness in the temporal quadrant was 38.5 (14.1) μm in the corticosteroid group and 44.5 (12.7) μm in the PE group (P=.02). In multivariate analysis, PE treatment was the only independent factor associated with a visual acuity greater than 20/200.
CONCLUSION: In optic neuritis associated with NMO, sequential treatment with pulsed intravenous corticosteroids and PE is more effective than standard monotherapy with corticosteroids on visual acuity outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22776923     DOI: 10.1001/archophthalmol.2012.1126

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  40 in total

1.  Comparison of field-of-view optimized and constrained undistorted single-shot diffusion-weighted imaging and conventional diffusion-weighted imaging of optic nerve and chiasma at 3T.

Authors:  Yuan Tian; Junqing Wang; Mingge Li; Xin Lou; Jing Tang; Quangang Xu; Yingkui Zhang; Shihui Wei; Lin Ma
Journal:  Neuroradiology       Date:  2018-07-19       Impact factor: 2.804

2.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

Review 3.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 4.  Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.

Authors:  Deena A Tajfirouz; M Tariq Bhatti; John J Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 5.  Neuromyelitis Optica (Devic's Syndrome): an Appraisal.

Authors:  Teresa M Crout; Laura P Parks; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

Review 6.  The Diagnosis and Treatment of Optic Neuritis.

Authors:  Helmut Wilhelm; Martin Schabet
Journal:  Dtsch Arztebl Int       Date:  2015-09-11       Impact factor: 5.594

7.  Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Authors:  Hesham Abboud; Alex Petrak; Maureen Mealy; Sarana Sasidharan; Laila Siddique; Michael Levy
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

8.  Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial.

Authors:  Heather E Moss; Weihua Gao; Laura J Balcer; Charlotte E Joslin
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

Review 9.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

Review 10.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.